There were 1,553 press releases posted in the last 24 hours and 450,143 in the last 365 days.

Solid Biosciences Announces Upcoming Preclinical Data Presentations

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held May 16-19, 2018 in Chicago.

Oral Presentations:

Poster Presentations:

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. Solid’s lead clinical candidate for DMD is a novel adeno-associated viral (AAV) vector-mediated microdystrophin gene transfer called SGT-001. The Phase I/II clinical trial for SGT-001, IGNITE DMD, is currently on clinical hold.  For more information, please visit

Solid Biosciences
Kate Niazi-Sai
+1 617-337-4680

Primary Logo